Astellas Licenses U.S., Europe Rights To Kidney-Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma said it has licensed rights from U.S.-based Aveo Pharmaceutical to develop AV-951 (tivozanib) in Europe and the United States